Takeda Pharmaceutical Industries is just the latest major drugmaker to announce its aims for big growth in China. But this time, the company isn’t looking for triple or even quadruple its current sales in the country. It’s looking to boost its Chinese revenues tenfold. President Yasuchika Hasegawa freely admits that the company’s been trying for [...]
Boehringer Ingelheim and co-marketer Pfizer could make a bid to capture more of the respiratory drug market. In a new study, the company’s Spiriva drug proved as effective as GlaxoSmithKline’s Serevent in helping asthmatic adults breathe better. Spiriva is currently approved for COPD, or smoker’s lung, so moving it into the asthma market could boost [...]
Drug counterfeiting has become a $200-billion business annually, according to the World Customs Organization. By some calculations, the counterfeiting trade has become more lucrative than the narcotics business. It’s a global problem. The World Health Organization estimates that counterfeit drugs make up ten percent of the drug market worldwide. And experts say that solving it–or [...]
More drugs are hitting the recall list these days. As CNN Money reports, the number of recalls hit 1,742 last year–that’s an increase of 309 percent over 2008. “We’ve seen a trend where the last four years are among the top five for the most number of drug recalls since we began tallying recalls in [...]
In a bid to break out of its dependence on manufacturing and cheap labor, the Chinese government is planning to invest $1.5 billion into new drug development between 2011 and 2016. And biotechnology is one of seven emerging industries that the Asian powerhouse will use to spearhead the next big step in its economic development, [...]
The following listing is of the top U.S. generic companies based on sales from Jan-Dec 2009. In recent years, Big Pharma has begun to look beyond brand-name drugs to the generics market. With the rising costs of healthcare, governments and payers alike are pushing for increased generics usage. And Big Pharma companies like Novartis and [...]
With Genzyme in the news, we’ve all been hearing plenty about the wave of M&A deals that’s been rolling through the world’s life sciences industry. Last year, Thomson Reuters tracked more than 1,400 such deals worth $206 billion worldwide, giving the Boston Globe the hard numbers it needs to assert that this is one trend [...]
Think Pfizer (NYSE: PFE) has had enough of buyouts for awhile, now that it’s partially digested the $68 billion Wyeth acquisition? Think again. CFO Frank D’Amelio told the German newspaper Handelsblatt that the company is scouting for potential buys in several specific areas, including emerging markets.
GlaxoSmithKline (NYSE: GSK) has agreed to pay more than $1 billion of its $2.4 billion legal expense budget to settle hundreds of Paxil birth defect lawsuits. Families whose children were born with birth defects after their mothers used Paxil will each get an average of $1.2 million from the company. The settlement covers more than 800 of the [...]
Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for [...]
You are currently browsing the weblog archives.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News